Stock Alert for BioCryst Pharmaceuticals Inc. (BCRX) - The Market Financial

Stock Alert for BioCryst Pharmaceuticals Inc. (BCRX) The Market Financial Additionally, BCRX has a third product candidate, BCX4208 — a next generation PNP inhibitor — in mid-stage trials for the treatment of gout. ... and more »

Regeneron's Billion Research Push Mimics Genentech - BusinessWeek

Regeneron's Billion Research Push Mimics Genentech BusinessWeek ... a successful study result in its new drug for treating gout, the first of three new treatments that may generate at least billion a year in revenue. ... Regeneron gout drug works in one trial, fails otherReuters Regeneron Sees Mixed Results on Gout Drug TrialsWall Street Journal All About Gout: Arcalyst Meets Phase III Prophylaxis EndpointBioWorld Online Motley Fool -Monthly Prescribing Reference -TopNews United States all 74 news articles »

Gout Drug May Decrease LVH in CKD Patients - Renal and Urology News

Gout Drug May Decrease LVH in CKD Patients Renal and Urology News The study is the first to show that allopurinol treatment is associated with these effects in CKD patients. Investigators postulate that these effects may ...

CRWEWallstreet.com reports on PWRM, XOMA, STEM - TMCnet

CRWEWallstreet.com reports on PWRM, XOMA, STEM TMCnet Prior to enrolling, patients were on a stable regimen of metformin monotherapy for at least 12 weeks before treatment with XOMA 052 or placebo. ... and more »